Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo

Executive Summary

Will develop camptothecin analogs under an exclusive worldwide licensing agreement with the independent research organization Research Triangle Institute announced Aug. 29. The synthetic analogs, which are based on a compound isolated from a Chinese tree, (ITALICS)Camptotheca auminata,(END ITALICS) have shown promise in inhibiting an enzyme required for cell replication and may therefore have potential as anticancer agents. In return for worldwide rights, Glaxo will provide RTI funds to support research and pay royalties on eventual product sales.
UsernamePublicRestriction

Register

PS018004

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel